Abstract

Although miR-133 mitigates cardiac hypertrophy and fibrosis, fine tunes β1-AR signaling, and protects against oxidative stress mediated apoptosis, it is unclear whether overexpression of miR-133a can ameliorate left ventricular function in failing hearts. Considering its multidisciplinary role in the heart, it is suggested that miR-133a is a master regulator of several networks that controls pathological cardiac remodeling. Therefore, it is a promising therapeutic target for heart failure.

Keywords: MicroRNA; Diabetes; Remodeling; Therapy; Regulation

Introduction

Despite gigantic stride made towards understanding Cardiovascular Diseases (CVD), heart failure remains the number one cause of morbidity and mortality across the globe, and accounts for 31.9% of all deaths in USA [1]. Heart is a highly sophisticated, vulnerable, and unique organ, which has responsibility to incessantly and efficiently function for survival of the individual. The heart is regulated at several levels by tiny regulatory RNAs called miRNAs [2-8]. MiRNAs are endogenous, evolutionary conserved and ~ 23 nucleotide long, non-coding RNAs that modulate genes by post transcription repression [9]. Differential expression of miRNAs are documented in pathological hearts that leads to cardiovascular diseases [2,10]. MiRNAs are emerged as a biomarker and promising therapeutic target for cardiovascular disease [2,3,11]. The human heart expresses more than 800 miRNAs amongst which miR-133a is the most abundant in human myocardium [12-14]. Abrogation of miR-133a impairs cardiac development at embryonic and postnatal stages [15]. The inhibition of only miR-133a can cause development of cardiac hypertrophy in adult mice [16]. Interestingly, transgenic overexpression of miR-133a does not show any phenotype but mitigates cardiac fibrosis in pressure overload (trans-aortic constriction) hearts [17]. MiR-133a is attenuated and contributes to cardiac hypertrophy in the diabetic hearts. Interestingly, overexpression of miR-133a mitigates cardiac fibrosis in diabetics [18-20].

However, whether overexpression of miR-133a can mitigate cardiac dysfunction in the failing heart is unclear. Here, a brief account of miR-133a transcription and its potential role in amelioration of cardiac dysfunction will be discussed.

Types of Mir-133 and their Transcription

There are two types of miR-133: miR-133a and miR-133b. MiR-133a has two alleles: miR-133a-1 and miR-133a-2. Both alleles of miR-133a are identical in sequence and differ from miR-133b by only two nucleotides. MiR-133a is expressed in the heart and in the skeletal muscle, whereas miR-133b is expressed only in the skeletal muscle and not in the heart. Both alleles of miR-133a and miR-133b are transcribed as bicistronic transcripts. MiR-133a-1 is encoded by chromosome 18 and transcribed as bicistronic cluster with miR-1-2. On the other hand miR-133a-2 is encoded by chromosome 2 and it transcribed as bicistronic transcript with miR-1-1. MiR-133b is located on chromosome 1 and is transcribed as a cluster with miR-206 [15]. The expression of miR-133a is regulated by myosin enhancer factor-2 (Mef2) and Serum Response Factor (SRF) in the myocardium [21,22].

Multidisciplinary Role of Mir-133a in Pathological Cardiac Remodeling

The two common pathological remodeling in the heart is hypertrophy and fibrosis. It is documented that miR-133a mitigates both hypertrophy and fibrosis suggesting that it is cardioprotective [16-18,20,23-25]. Recently, it is reported that miR-133a regulates several genes in the betal-adrenergic receptor (β1-AR) signaling cascade. The cardiac specific overexpression of miR-133 attenuates β1-AR mediated induction of apoptosis and fibrosis in the heart, and mitigates cardiac dysfunction in mice with transaortic constriction [23]. This is corroborated by the finding that carvedilol (a β-blocker) protects cardiomyocytes against oxidative stress induced apoptosis by up regulating miR-133 [24]. In human mesenchymal stem cell, miR-133a is demonstrated to promote cardiogenic differentiation by targeting epidermal growth factor receptor [25]. The cardiogenic differentiation is crucial for regeneration of myocardium and replenishment of damaged cardiomyocytes. In pathological hearts, fibroblasts turnover is increased and accumulated fibroblast causes fibrosis. This fibroblast can be reprogrammed into cardiomyocytes by a cocktail of miR-1, -133, -208, and -499 in mice [26]. Since cardiomyocytes undergo apoptosis and their number is less in failing hearts, the trans-differentiation of fibroblasts that causes fibrosis into cardiomyocytes is like converting devil into god and it can be harnessed for reverting pathological remodeling. Further analyses using human foreskin fibroblasts revealed that miR-133a in concert with other transcription factors contributes to reprogramming of fibroblast into cardiomyocytes [27].

It is established that miRNAs inhibits gene by binding to the 3’ UTR of the gene. Interestingly, recent studies revealed that mature miRNA can reenter into nucleus and bind to promoter region to up- or down-regulates a gene [28-32]. The binding of miRNA to promoter region is facilitated by recruitment of Chromatin Modifying Proteins (CMPs).

Citation: Mishra PK (2014) Is Mir-133a a Promising Therapeutic Target for Heart Failure? J Diabetes Metab 5: e118. doi:10.4172/2155-6156.1000e118

Copyright: © 2014 Mishra PK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The binding of miRNA to promoter region can activate transcription (RNA activation) if CMP recruitment increases H3K4 methylation. On the other hand, miRNA binding at promoter can silence gene transcription (transcriptional gene silencing) if CMP recruitment increases H3K9/27 methylation [28]. We have reported that miR-133a controls DNA methylation by regulating DNA methyl transferases in diabetic cardiomyocytes [18]. These findings suggest miR-133a has multiple roles and could be a master regulator of several regulatory networks in the heart.

**Potentialities and Limitations of Mir-133a as Therapeutic Target for Heart Failure**

Considering the role of miR-133a in regulation of cardiac hypertrophy, fibrosis, epigenetic modification, and β-AR signaling and our unpublished data on cardiac autophagy homeostasis, it is justified to suggest that miR-133a is a promising therapeutic target for cardiomyopathy [16-20,23,24]. However, more empirical data pertaining to improvement of left ventricular function and on toxicity in different heart failure models are required before it can be translated from bench to bedside.

**Sources of Funding**

This work was supported, in part, by National Institute of Health grants HL-113281 and HL-116205.

**References**

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014 Jan 21;129(3):e28-e342
2. Mishra PK, Tyagi N, Kumar M, Tyagi SC (2009) MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 13: 778-789.
3. Olson EN (2014) MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med 6: 239ps3.
4. Quidt D, Olson EN (2013) MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest 123: 11-18.
5. Small EM, Frost RJ, Olson EN (2010) MicroRNAs add a new dimension to cardiovascular disease. Circulation 121: 1022-1032.
6. Small EM, Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469: 336-342.
7. Topkara VK, Mann DL (2010) Clinical applications of miRNAs in cardiac remodeling and heart failure. Per Med 7: 531-548.
8. van Rooij E, Olson EN (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117: 2369-2376.
9. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
10. Chavali V, Tyagi SC, Mishra PK (2014) Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts. Cell Biochem Biophys 68: 25-35.
11. Tyagi AC, Sen U, Mishra PK (2011) Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases. Curr Diabetes Rev 7: 367-376.
12. Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, et al. (2013) A deep sequencing approach to uncover the miRNOME in the human heart. PLoS One 8: e57800.
13. McCarthy JJ, Esser KA (2007) MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Physiol (1985) 102: 306-313.
14. Melman YF, Shah R, Das S (2014) MicroRNAs in heart failure: is the picture becoming less mirky? Circ Heart Fail 7: 203-214.
15. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, et al. (2008) microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 22: 3242-3254.
16. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, et al. (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13: 613-618.
17. Malkovitch SJ, Wang W, Tu Y, Eschenbacher WH, Dom LE, et al. (2010) MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ.Res. 106:166-175:166-75. PMCID:PMC2804031
18. Chavali V, Tyagi SC, Mishra PK (2012) MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. Biochem Biophys Res Commun 425: 668-672.
19. Feng B, Chen S, George B, Feng Q, Chakrabarti S (2010) mir133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 26: 40-49.
20. Chen S, Puthanveetil P, Feng B, Malkovitch SJ, Dom GW 2nd, et al. (2014) Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 18: 415-421.
21. Liu N, Williams AH, Kim Y, McNally J, Bezprozvannaya S, et al. (2007) An intragenic MEF2-dependent enhancer directly modulates specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A 104: 20844-20849.
22. Zhao Y, Samal E, Srivastava D (2005) Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436: 214-220.
23. Castaldi A, Zaglia T, Di Mauro V, Carullo P, Viggiani G, et al. (2014) MicroRNA-133 Modulates theβ1-Adrenergic Receptor Transduction Cascade. Circ Res 115: 273-283.
24. Xu C, Hu Y, Hou L, Ju J, Li X, et al. (2014) β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. J Mol Cell Cardiol 75:11-121.
25. Lee SY, Ham O, Cha MJ, Song BW, Choi E, et al. (2013) The promotion of cardiogenic differentiation of hMSCs by targeting epidermal growth factor receptor using microRNA-133a. Biomaterials 34: 92-99.
26. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, et al. (2012) MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 110: 1465-1473.
27. Nam YJ, Song K, Luo X, Daniel E, Lambeth K, et al. (2013) Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci U S A 110: 5588-5593.
28. Huang V, Li LC (2012) microRNA goes nuclear. RNA Biol 9: 269-273.
29. Liao JY, Ma LM, Guo YH, Zhang YC, Zhou H, et al. (2010) Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A 104: 20844-20849.
30. Huang V, Place RF, Portnoy V, Wang J, Qi Z, et al. (2012) Upregulation of Cyclin B1 by microRNA and its implications in cancer. Nucleic Acids Res 40: 1695-1707.
31. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R (2008) MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A 105: 1608-1613.
32. Younger ST, Corey DR (2011) Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res 39: 5682-5691.